Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment

Patricia Diaz-Galvan1†, Giulia Lorenzon2†, Rosaleena Mohanty2, Gustav Mårtensson2, Enrica Cavedo3, Simone Lista3, Andrea Vergallo3, Kejal Kantarci1, Harald Hampel3, Bruno Dubois3, Michel J. Grothe4,5, Daniel Ferreira1,2† and Eric Westman2,6*†

Correction: Alz Res Ther 15, 117 (2023)
https://doi.org/10.1186/s13195-023-01253-2

Following publication of the original article [1], the authors identified an error to the titles and labels of axes in Figs. 3 and 4, as well as the captions of treatment groups on Fig. 4. This error does not affect the accuracy and clarity of the research presented, neither does affect the interpretation of the results. The corrected figures are given below.

Error:

- In Fig. 3A (Scatterplot of the hippocampus-to-cortex ratio by BV/CSF index), labels indicating the MRI subtypes are in the reverse order.
  - In the X axis, which corresponds to the “TYPICALITY-Hippocampus-to-cortex ratio”, labels should go from “Limbic-predominant” (on the left) to “Hippocampal-sparing” (on the right).
  - In the Y axis, which corresponds to the “SEVERITY-BV:CSF index”, labels should go from “Minimal atrophy” (at the top) to “Typical AD” (at the bottom).

- In Fig. 4 (interaction plots between severity/typicality subtyping dimension and treatment in the MRI efficacy measures), captions of the lines indicating the treatment groups are in reversed order. Red lines correspond to the placebo group (not to the donepezil group), and blue lines correspond to the donepezil group (not to the placebo group).

- In Fig. 4C (interaction plot between typicality subtyping dimension and APC of lateral ventricle volume), axes titles are incorrect.
  - X axis title should be “TYPICALITY-Hippocampus-to-cortex ratio”, instead of “SEVERITY-BV:CSF index”.

†Patricia Diaz-Galvan and Giulia Lorenzon are shared first authors.
†Daniel Ferreira and Eric Westman are shared senior authors.

The original article can be found online at https://doi.org/10.1186/s13195-023-01253-2.

*Correspondence:
Eric Westman
eric.westman@ki.se
1 Department of Radiology, Mayo Clinic, Rochester, MN, USA
2 Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
3 Alzheimer Precision Medicine (APM), Sorbonne University, AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l’hôpital, Paris, France
4 Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Seville, Spain
5 Wallenberg Center for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
6 Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, UK

© The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
The original article [1] has been updated.
Fig. 4  Interaction plots between severity/typicality subtyping dimensions (X axis) and treatment (Y axis) in APC of AD signature cortical thickness which includes entorhinal, inferior temporal, middle temporal, and fusiform gyri thickness (A, B) and APC of lateral ventricle volume (C).

Published online: 14 October 2023

Reference